Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Novartis to Start China Trial of Novel Cancer Drug in 2013

publication date: Sep 20, 2010
The China R&D center for Novartis plans to put its first novel cancer treatment into Phase I testing in 2013. Although details of the new drug candidates were not released, Novartis said the new molecules are aimed specifically at treating cancers that are most prevalent in China, which include gastric, liver, nasopharyngeal and esophageal cancer. The China trial would be the first-in-human test of the drug candidate.  More details....

Stock Symbol: (NYSE: NVS)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital